US2610186A - Oroshnik - Google Patents

Oroshnik Download PDF

Info

Publication number
US2610186A
US2610186A US2610186DA US2610186A US 2610186 A US2610186 A US 2610186A US 2610186D A US2610186D A US 2610186DA US 2610186 A US2610186 A US 2610186A
Authority
US
United States
Prior art keywords
contractions
compound
amino
parts
isocytosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Publication date
Application granted granted Critical
Publication of US2610186A publication Critical patent/US2610186A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • This invention relates to certain therapeutically eiiective organic compounds which are derivatives of isocytosine, 2-amino-4-hydroxypyrimidine and to their use as therapeutic agents having the ability to depress contractions of the uterus. More specifically this invention relate to Z-amino- 4 dialkylaminoethoxypyrimidines and 2 amino 4 dialkylaminoethoxy 6 methylpyrimidines in which each alkyl group is an isobutyl radical or an aliphatic radical having more than four and less than nine carbon atoms.
  • the said isocytosine derivatives having the ability to depress contractions of the uterus may be represented by the following graphic formula:
  • R and R" are each an isobutyl radical or an aliphatic radical having more than four and less than nine carbon atoms, and in which R" is hydrogen or methyl.
  • the derivatives of isocytosine which embody this invention may be used as such to depress contractions of the uterus. They may also be used as in the form of salts of the isocytosine derivatives with organic or inorganic acids and since the said derivatives are basic in character, they may be readily converted into salts having substantially more solubility in water than the free bases. Salts such as the succinate, maleate,
  • salts of simple low-molecular weight aliphatic organic acids as well as salts of the free bases with inorganic acids may be readily prepared from the free bases and are highly. effective therapeutically.
  • the new and novel derivatives of isocytosine to which the present invention is directed have considerable value which renders their use as pharmaceutical products highly advantageous either alone or with known pharmacological products.
  • the ability of these novel substances to depress contractions of the uterus has been 6 Claims. (01. see-256A) shown by a number of experiments in which a salt of the isocytosine derivative was added to a bath of nutrient solution having a strip of albino rat uterine tissue suspended therein. A continu ous kymographic record was made of contractions of the uterine strip before and after addi tion to the bath of a salt of an isocytosine derivative.
  • isocytosine which are homologues of the class of isocytosine derivatives specifically mentioned before as having therapeutic value were also tested in the same way to determine their effect on contractions oi the uterus.
  • The'succinate salts or the hydrochloride salts of the following compounds were tested for their pharmacologicalproperty of depressing contractionsof the uterus:
  • Figures 1-9 are kymographic records of contractions of the strip of uterine tissue before and after addition to the bath of the comtaining no isocytosine derivative. That portion 4 of Figures 1-9 after the letter I) represents contractions as they return t normal and after the uterine strip is no longer in contact with a-compound being tested for its effect on contractions of uterine tissue.
  • Figure 1 shows the addition of milligrams of the succinate salt of compound I to the bath produced an almost immediate effect on the contractions of th uterine tissue which amounted to a substantially complete cessation of contractions.
  • Figure 2 shows the addition of 5 milligrams of the succinate salt of compound II caused a rapid diminishing of the contractions of the strip of uterine tissue followed by an almost complete cessation of contractions and an appreciable lowering of the tonus of the issue.
  • Compound II formed a succinate salt in which four molecules of this compound were combined with five molecules of succinic acid.
  • Figure 3 shows that the addition to the bath of 5 milligrams of compound III in the form of its hydrochloride salt produced a gradual decreas in-amplitude of contractions of the uterine strip followed by a short period when the uterine tissue was not contracting.
  • Figure 4 shows the addition to the bath of 5 milligrams of compound IV in the form of its hydrochloride salt produced a marked decrease in amplitude of contractions of the uterine tissue and a slight decreasein tonus, as well as a slight decrease in frequency. of contractions.
  • Figure 5 shows the addition of 5 milligrams of the succinate salt of compound V produced an immediate cessation of contractions of the strip of uterine tissue and a slight lowering of tonus of the tissue.
  • Figure 6 shows the addition of 5 milligrams of the succinate salt of compound VI produced a very rapid decline in amplitude of contractions and a substantiallowering of tonus of the strip of uterine tissue. Frequency of contractions of the tissue was increased.
  • Compound VI formed a succinate salt in which four molecules of this compound were combined with five molecules of succinic acid.
  • Figures '7, 8, and 9 show only slight effects on the uterine tissue result from the addition to the bath of the sesquisuccinate salts of compounds VII, VIII, and IX.
  • Figure 7 shows the addition of milligrams of the sesquisuccinate salt of compound VII pro prised a slight decrease of amplitude of contractions
  • Figures 8 and 9 show the addition of 10 milligrams of the sesquisuccinate salts of compounds VIII and IX, respectively, to the bath produced a slight increase in amplitude of contractions and a slight increase in tonus of the uterine muscular tissue; however, compounds VII, and VIII and IX had .no appreciable. elfect on the frequency of contractions of the uterine muscular tissue.
  • Tonus is a natural property of muscle and'is a measure of degree of contraction independent of external influences.
  • the degree of contraction produced by a stimulant depends upon the level of tonus, and, therefore, some investigators 4 have defined tonus as the resistance offered to extension.
  • Amplitude may be defined as the height of a contraction wave measured from the base level to the peak of the wave; base level being the average lower level of the contractions.
  • Frequency is the number of contraction waves in a unit time period.
  • Derivatives of isocytosine such as 2-amino-4- dialkylaminoethoxypyrimidine and 2-amino-4- dialkylaminoethoxy-S-methylpyrimidine may be prepared by reacting 2-amino-4-chloropyrimidin or 2-amino-4-chloro-6-methylpyrimidine,
  • a water-soluble succinate salt of the compound prepared above was made by dissolving 3.1 grams of free base and 1.4 grams of succinic acid in 12 cc. of boiling acetone. Upon cooling the acetone solution, a succinate salt of the pyrimidine base precipitated and was recrystallized from 10 cc. of hot acetone. 3.4 grams of the succinate salt of the pyrimidine base having a melting point of 98-99 C. were obtained and this crystalline salt had the following formula: V
  • reaction mixture was refluxed for one hour and cooled and then 100 parts of water containing 10 parts of dissolvedsodium hydroxide were added with stirring to the cooled reaction mixture. After stirring had been stopped, two layers were formed and the organic layer was decanted, dried over anhydrous potassium carbonate and the solvents, benzene and xylene, were removed by distillation. The residue in the distillation flask was distilled at a temperature of 100-110 C. and a pressure of 0.001 mm. of mercury. 160 parts of Z-amino 4 diisobutylaminoethoxy 6 methylpyrimidine were obtained.
  • a water-soluble succinate salt of the pyrimidine base was made by dissolving 4.1 grams of the pyrimidine base and 1.7 grams of succinic acid in 10 cc. of boiling acetone. Upon cooling the acetone solution, a white solid precipitated and it was removed and recrystallized from hot acetone. 3.5 grams of the recrystallized material were obtained and had a melting point of 99-100 C.
  • the crystalline succinate salt of the pyrimidine base had the following formula:
  • R. and R each is selected from the group 6 of alkyl radicals consisting of an isobutyl radical and alkyl radical having at least five and less than nine carbon atoms, and in which R" is selected from the group of radicals consisting of hydrogen and methyl.
  • R and R are each an isobutyl radical and R is hydrogen.
  • R and R are each a normal amyl radical and R" is hydrogen.
  • R. and R are each an isoamyl radical and R" is hydrogen.
  • R and R are each an isobutyl radical and R," is a methyl radical.
  • R and R. are each a normal amyl radical and R" is a methyl radical.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

Sept. 9, 1952 w. OROSHNIK 2,610,185
2-AMINO-4-DIALKYLAMINOETHOXYPYRIMIDINES Filed NOV. 7, 1950 2 SHEETS-SHEET l T1 g1. T4 :12.
I 0 b Q b Fig.3.
l I a b I INVENTOR .W/LL/AM OROSHN/K.
S p 9, 1952 w. OROSHNIK 2,610,186
2-AMINO4DIALKYLAMINOETHOXYPYRIMIDINES "Fig.7.
Filed Nov. '7, 1950 2 SHEETS SHEET 2 Fig.5.
' INVENTOR W/LL/AM OPDSHN/K.
Paten te cl Sept. 9, 1952 William Oroshnik, Plainfield, N. .L, assignor to Ortho Pharmaceutical Corporation, a corporation of New Jersey Application November 7, 1950, Serial No. 194,531
This invention relates to certain therapeutically eiiective organic compounds which are derivatives of isocytosine, 2-amino-4-hydroxypyrimidine and to their use as therapeutic agents having the ability to depress contractions of the uterus. More specifically this invention relate to Z-amino- 4 dialkylaminoethoxypyrimidines and 2 amino 4 dialkylaminoethoxy 6 methylpyrimidines in which each alkyl group is an isobutyl radical or an aliphatic radical having more than four and less than nine carbon atoms. The said isocytosine derivatives having the ability to depress contractions of the uterus may be represented by the following graphic formula:
l R NEE-C .\CLO-CH2-CH2N/ N C--H in which R and R" are each an isobutyl radical or an aliphatic radical having more than four and less than nine carbon atoms, and in which R" is hydrogen or methyl.
A number of derivatives of isocytosine have been prepared and studied for various pharmaceutical and medicinal uses but it is believed that the particular derivatives of isocytosine with which this invention is concerned are new substances. It is also believed the ability of these substances to depress contractions of the uterus has not been known heretofore.
The derivatives of isocytosine which embody this invention may be used as such to depress contractions of the uterus. They may also be used as in the form of salts of the isocytosine derivatives with organic or inorganic acids and since the said derivatives are basic in character, they may be readily converted into salts having substantially more solubility in water than the free bases. Salts such as the succinate, maleate,
tartrate, lactate, fumarate and the like are preferred, but salts of simple low-molecular weight aliphatic organic acids as well as salts of the free bases with inorganic acids, may be readily prepared from the free bases and are highly. effective therapeutically.
The new and novel derivatives of isocytosine to which the present invention is directed have considerable value which renders their use as pharmaceutical products highly advantageous either alone or with known pharmacological products. The ability of these novel substances to depress contractions of the uterus has been 6 Claims. (01. see-256A) shown by a number of experiments in which a salt of the isocytosine derivative was added to a bath of nutrient solution having a strip of albino rat uterine tissue suspended therein. A continu ous kymographic record was made of contractions of the uterine strip before and after addi tion to the bath of a salt of an isocytosine derivative. Additional derivatives of isocytosine which are homologues of the class of isocytosine derivatives specifically mentioned before as having therapeutic value were also tested in the same way to determine their effect on contractions oi the uterus. The'succinate salts or the hydrochloride salts of the following compounds were tested for their pharmacologicalproperty of depressing contractionsof the uterus:
Compound 1-2-amino-4-diisobutylaminoethoxypyrimidine v p Compound II-2 amino-l-di-n-amylaminoethoxypyrimidine Compound III-2 amino-4-diisoamylaminoethoxypyrimidine Compound IV2-amino 4 diisooctylaminoethoxypyrimidine Compound V2-amino 4 diisobutylaminoethoxy-6-methylpyrimidine Compound .VI--2 amino-4-di-n-amy1aminoethoxy-G-methylpyrimidine Compound VlI2-amino 4 dimethylaminoethoxypyrimidine Compound VIII-2-amino 4 diethylaminoethoxypyrimidine Compound IX-2-aminol-diethy1aminoethoxy- G-methylpyrimidine V The following procedure was employed in test" ing the effect of. compounds LIX on. a rat uterus: A female albino rat weighing from 150-390 milligrams was killed by a blow on the head and the uterus was removed. A strip of the uterine tissue was suspended in a cc. bath of an aerated Ringer-Locke solution. One end of the uterine strip was maintained in a stationary position and the other end was attached to a lever which made contact with a kymograph and con tinuously recorded contractions. After a short period of immersion in the bath, the strip of uterine tissue was contracting rhythmically and normally, and at this point an aqueous solution of a succinate salt or a hydrochloride salt of the isocytosine derivative to be tested for its effect on contractions of uterine tissue was added to the bath. Figures 1-9 are kymographic records of contractions of the strip of uterine tissue before and after addition to the bath of the comtaining no isocytosine derivative. That portion 4 of Figures 1-9 after the letter I) represents contractions as they return t normal and after the uterine strip is no longer in contact with a-compound being tested for its effect on contractions of uterine tissue.
Figure 1 shows the addition of milligrams of the succinate salt of compound I to the bath produced an almost immediate effect on the contractions of th uterine tissue which amounted to a substantially complete cessation of contractions. Figure 2 shows the addition of 5 milligrams of the succinate salt of compound II caused a rapid diminishing of the contractions of the strip of uterine tissue followed by an almost complete cessation of contractions and an appreciable lowering of the tonus of the issue. Compound II formed a succinate salt in which four molecules of this compound were combined with five molecules of succinic acid. Figure 3 shows that the addition to the bath of 5 milligrams of compound III in the form of its hydrochloride salt produced a gradual decreas in-amplitude of contractions of the uterine strip followed by a short period when the uterine tissue was not contracting. Figure 4 shows the addition to the bath of 5 milligrams of compound IV in the form of its hydrochloride salt produced a marked decrease in amplitude of contractions of the uterine tissue and a slight decreasein tonus, as well as a slight decrease in frequency. of contractions. Figure 5 shows the addition of 5 milligrams of the succinate salt of compound V produced an immediate cessation of contractions of the strip of uterine tissue and a slight lowering of tonus of the tissue. Figure 6 shows the addition of 5 milligrams of the succinate salt of compound VI produced a very rapid decline in amplitude of contractions and a substantiallowering of tonus of the strip of uterine tissue. Frequency of contractions of the tissue was increased. Compound VI formed a succinate salt in which four molecules of this compound were combined with five molecules of succinic acid. Figures '7, 8, and 9 show only slight effects on the uterine tissue result from the addition to the bath of the sesquisuccinate salts of compounds VII, VIII, and IX. Figure 7 shows the addition of milligrams of the sesquisuccinate salt of compound VII pro duced a slight decrease of amplitude of contractions and Figures 8 and 9 show the addition of 10 milligrams of the sesquisuccinate salts of compounds VIII and IX, respectively, to the bath produced a slight increase in amplitude of contractions and a slight increase in tonus of the uterine muscular tissue; however, compounds VII, and VIII and IX had .no appreciable. elfect on the frequency of contractions of the uterine muscular tissue.
Tonus is a natural property of muscle and'is a measure of degree of contraction independent of external influences. The degree of contraction produced by a stimulant depends upon the level of tonus, and, therefore, some investigators 4 have defined tonus as the resistance offered to extension.
Amplitude may be defined as the height of a contraction wave measured from the base level to the peak of the wave; base level being the average lower level of the contractions.
Frequency is the number of contraction waves in a unit time period.
Derivatives of isocytosine, such as 2-amino-4- dialkylaminoethoxypyrimidine and 2-amino-4- dialkylaminoethoxy-S-methylpyrimidine may be prepared by reacting 2-amino-4-chloropyrimidin or 2-amino-4-chloro-6-methylpyrimidine,
-respectively, with a sodium salt of a dialkylami- 'noethanol.
EXAMPLE I Preparation of 2 -amino-4-.diisobutylaminocaribou/pyrimidine Twenty-five parts of sodium metal were slowly added to 200 parts of diisobutylaminoethanol, dissolved in 500 parts of xylene. Twelve hundred parts of benzene were then added to the resulting sodium salt of diisobutylaminoethanol. One hundred twenty-nine parts of 2-amino-4-chloropyrimidine were added to the above solution-and during the addition the solution was cooled sufficiently to maintain the temperature at C. After the addition was complete, the reaction mixture was refluxed forone hour and cooled and then parts of water containing 10 parts of dissolved sodium hydroxide were added with stirring to the cooled reaction mixture. At this point two layers were formed and the organic layer was decanted. dried over anhydrous potassium carbonate, and the solvents, benzene and xylene, were removed by distillation. The residue in the distillation flask was distilled at a temperature of 108l12 C. and a pressure of 0.001 mm. of mercury. One hundred seventy-two parts of 2- amino4-diisobutylaminoethoxypyrimidine were obtained.
A water-soluble succinate salt of the compound prepared above was made by dissolving 3.1 grams of free base and 1.4 grams of succinic acid in 12 cc. of boiling acetone. Upon cooling the acetone solution, a succinate salt of the pyrimidine base precipitated and was recrystallized from 10 cc. of hot acetone. 3.4 grams of the succinate salt of the pyrimidine base having a melting point of 98-99 C. were obtained and this crystalline salt had the following formula: V
(C14H26N4'O) (C4H604) EXAMPLE 11' Preparation of Z-amz'rio 4 diisobutylaminoethoxy-fi-methylpyrimidine Twenty-five parts of sodium metal were slowly added to 200 parts of diisobutylaminoethanol, dissolved in 500 parts'of xylene. Twelve hundred parts of benzene were then added to the resulting sodium salt of diisobutylaminoethanol. One hundred forty-three parts of 2-amino-4-chloro- 6-methylpyrimidine were added to the above solution and during the addition the solution was cooled suniciently to maintain the temperature at 80 C. After the addition was complete, the reaction mixture was refluxed for one hour and cooled and then 100 parts of water containing 10 parts of dissolvedsodium hydroxide were added with stirring to the cooled reaction mixture. After stirring had been stopped, two layers were formed and the organic layer was decanted, dried over anhydrous potassium carbonate and the solvents, benzene and xylene, were removed by distillation. The residue in the distillation flask was distilled at a temperature of 100-110 C. and a pressure of 0.001 mm. of mercury. 160 parts of Z-amino 4 diisobutylaminoethoxy 6 methylpyrimidine were obtained.
A water-soluble succinate salt of the pyrimidine base was made by dissolving 4.1 grams of the pyrimidine base and 1.7 grams of succinic acid in 10 cc. of boiling acetone. Upon cooling the acetone solution, a white solid precipitated and it was removed and recrystallized from hot acetone. 3.5 grams of the recrystallized material were obtained and had a melting point of 99-100 C. The crystalline succinate salt of the pyrimidine base had the following formula:
(CH28N40) ((3411604) What is claimed is: l. A compound having the structural formula NH? O in which R. and R each is selected from the group 6 of alkyl radicals consisting of an isobutyl radical and alkyl radical having at least five and less than nine carbon atoms, and in which R" is selected from the group of radicals consisting of hydrogen and methyl.
2. A compound according to claim 1 in which R and R are each an isobutyl radical and R is hydrogen.
3. A compound according to claim 1 in which R and R are each a normal amyl radical and R" is hydrogen.
4. A compound according to claim 1 in which R. and R are each an isoamyl radical and R" is hydrogen.
5. A compound according to claim 1 in which R and R are each an isobutyl radical and R," is a methyl radical.
6. A compound according to claim 1 in which R and R. are each a normal amyl radical and R" is a methyl radical.
WILLIAM OROSHNIK.
REFERENCES CITED The following references are of record in the file of this patent:
Sutherland et al.: J. Org. Chem. 14, 235-238 (1949).
Braker et al.: J. Am. Chem. Soc. '69, 307243078 (1947).

Claims (1)

1. A COMPOUND HAVING THE STRUCTURAL FORMULA
US2610186D Oroshnik Expired - Lifetime US2610186A (en)

Publications (1)

Publication Number Publication Date
US2610186A true US2610186A (en) 1952-09-09

Family

ID=3439234

Family Applications (1)

Application Number Title Priority Date Filing Date
US2610186D Expired - Lifetime US2610186A (en) Oroshnik

Country Status (1)

Country Link
US (1) US2610186A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980781A (en) * 1966-03-31 1976-09-14 Imperial Chemical Industries Limited Fungicidal composition and method containing 2-amino-pyrimidines
US4000138A (en) * 1966-03-31 1976-12-28 Imperial Chemical Industries Limited Organic compounds and compositions containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980781A (en) * 1966-03-31 1976-09-14 Imperial Chemical Industries Limited Fungicidal composition and method containing 2-amino-pyrimidines
US4000138A (en) * 1966-03-31 1976-12-28 Imperial Chemical Industries Limited Organic compounds and compositions containing them

Similar Documents

Publication Publication Date Title
EP0031954B1 (en) Sulphonamides, process for their preparation and medicines containing these compounds
Turner et al. Studies on imidazole compounds. I. 4-Methylimidazole and related compounds
DK156717B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF INDOMETHACIN DERIVATIVES
CA1086735A (en) Piperidino-quinazolines
US3639477A (en) Novel propoxyguanidine compounds and means of producing the same
US2610186A (en) Oroshnik
NO771610L (en) PROCEDURES FOR THE PREPARATION OF KINAZOLIN DERIVATIVES
US2399601A (en) Substituted imidazoles
US2470085A (en) Substituted amino alkyl tetrazoles
Miller et al. Substituted sulfanilamides. I. N4-acyl derivatives
US2606195A (en) Aryl pyridyl carbinol ethers
US2610187A (en) Oroshnik
Fox et al. N, N'-SUBSTITUTED ETHYLENEDIAMINE DERIVATIVES
US4310532A (en) Methods and piperidinyl-alkyl-benzamide composition for inhibiting H2 histamine receptors
US3536723A (en) P - (2 - alkyloxy - benzoyl) - aminobenzoates of n - dialkylamine - alkyl and their quaternary salts
US2819269A (en) Carbalkoxy piperazine compounds
US2786059A (en) Derivatives of 2-nu-methyl-1, 2, 3, 4-tetrahydro-gamma-carbolines
US2610184A (en) Oroshnik
US3213140A (en) 2-phenyl-4, 6-dichlorophenoxyethylamine and salts thereof
US2497394A (en) Alkylaminoalkyl benzoates
SU845778A3 (en) Method of preparing 5-puenyl-1h-banzazepins or their salts
Hayes et al. Some Furan Antihistaminic Agents
US2566376A (en) Beta-tertiary aminoethanol ethers of diaryl pyridyl carbinols
US2746901A (en) Glycinamide salts
US2905590A (en) Thioxanthene derivative